Paclitaxel trevatide (formerly known as ANG 1005 or GRN 1005) is a paclitaxel-peptide drug conjugate, where three paclitaxel molecules linked by a cleavable succinyl ester linkage to a brain peptide vector, Angiopep-2. Paclitaxel trevatide is an oncology product to leverage the low-density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer cells. This drug successfully completed phase II clinical trials in breast cancer patients with recurrent brain metastases and in patients with high-grade glioma. 30-May-2014 Angiochem, the company that developed this drug, announced that the Food & Drug Association (FDA) had granted both orphan drug and fast track designation to paclitaxel trevatide for the treatment of glioblastoma multiforme (GBM). In addition, paclitaxel trevatide is going to be involved in phase III clinical trial to see if this drug can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with the newly diagnosed leptomeningeal disease and previously treated brain metastases.

Glepaglutide (also known as ZP 1848), a long-acting glucagon-like peptide-2 (GLP-2) analog that was developed for patients with reduced or complete loss of intestinal function. In October 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare disease short bowel syndrome (SBS). Many people with SBS are dependent on the frequent intake of intravenous fluids and nutrition delivered through a central catheter. Currently, glepaglutide is participating in a phase III clinical trial to determine the safety and efficacy of subcutaneous injection of the drug for the treatment of SBS.